Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Savant Capital LLC

Savant Capital LLC boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 42.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 31,525 shares of the company's stock after acquiring an additional 9,407 shares during the period. Savant Capital LLC's holdings in Apellis Pharmaceuticals were worth $1,006,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in APLS. Wolverine Asset Management LLC acquired a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at about $27,000. True Wealth Design LLC acquired a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at about $27,000. Capital Performance Advisors LLP purchased a new position in Apellis Pharmaceuticals in the 3rd quarter valued at about $56,000. KBC Group NV lifted its holdings in Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company's stock valued at $76,000 after purchasing an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company's stock valued at $130,000 after purchasing an additional 781 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Trading Up 1.2 %

NASDAQ APLS traded up $0.34 during mid-day trading on Tuesday, hitting $27.74. The company's stock had a trading volume of 386,302 shares, compared to its average volume of 1,754,469. Apellis Pharmaceuticals, Inc. has a 52-week low of $24.34 and a 52-week high of $71.90. The stock's fifty day simple moving average is $31.05 and its two-hundred day simple moving average is $32.03. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The firm has a market capitalization of $3.45 billion, a P/E ratio of -13.68 and a beta of 0.96.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 2,824 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total value of $83,364.48. Following the completion of the sale, the chief executive officer now owns 415,695 shares of the company's stock, valued at $12,271,316.40. This trade represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel David O. Watson sold 4,965 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total transaction of $142,495.50. Following the completion of the sale, the general counsel now directly owns 107,756 shares of the company's stock, valued at $3,092,597.20. This trade represents a 4.40 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,365 shares of company stock worth $1,810,479. Company insiders own 6.80% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Morgan Stanley assumed coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an "equal weight" rating and a $31.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a report on Thursday, February 13th. Royal Bank of Canada restated a "sector perform" rating and issued a $26.00 target price on shares of Apellis Pharmaceuticals in a report on Wednesday, January 29th. Robert W. Baird reduced their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an "outperform" rating on the stock in a report on Thursday, November 7th. Finally, Wells Fargo & Company reduced their target price on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an "equal weight" rating on the stock in a report on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).